News

ImmunityBio (IBRX) has been drawing attention after its lead product candidate Anktiva received FDA approval for use with BCG in certain bladder cancer patients, prompting investors to reassess the company’s broader immunotherapy pipeline and valuation. See our latest analysis for ImmunityBio. Since the FDA approval, ImmunityBio’s share price has cooled in the very short term, with 1-day and 7-day share price returns down 3% and 4.43%. However, the year-to-date share price return of 284.16%...

ImmunityBio received an FDA warning letter criticizing promotional claims for its lead product Anktiva. Following the warning letter, multiple class action lawsuits were filed alleging misleading statements and securities fraud. The issues center on whether the company accurately represented Anktiva's profile in marketing and investor communications. For investors tracking ImmunityBio (NasdaqGS:IBRX), this comes at a time when interest in the stock has been high, with a current share price...